Literature DB >> 21430337

The discovery and development of HIV therapy: the new challenges.

Carlo Federico Perno1.   

Abstract

The therapy of HIV infection has been dramatically improved over the years, and allowed the achievement of unexpected results. The availability of many drugs, and the knowledge of HIV related pathogenesis, helped in selecting highly effective antiviral therapies, yet today a major challenge stands, that is the selection of the best regimen(s) in clinical practice. In this frame, evidence-based medicine remains a cornerstone of modern medicine, but its structure needs to be adapted to the new challenges, made by an excess of information (not always fully reliable), by highly sophisticated statistical systems that may overlook the clinical practice despite their ability to define the statistical significance, and the limited number of independent controlled studies. The revision of the criteria of evidence-based medicine, and their adaptation to the new tools available, may allow a better contribution to the definition of the best therapy for each single patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430337     DOI: 10.4415/ANN_11_01_09

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  3 in total

1.  Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.

Authors:  Prashant Kumar; Yeruva Samrajya Lakshmi; Anand K Kondapi
Journal:  Pharm Res       Date:  2016-12-07       Impact factor: 4.200

2.  Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins.

Authors:  Humberto H Lara; Liliana Ixtepan-Turrent; Elsa N Garza Treviño; Dinesh K Singh
Journal:  J Nanobiotechnology       Date:  2011-09-18       Impact factor: 10.435

3.  Morphogenesis of the Infectious HIV-1 Virion.

Authors:  Jun-Ichi Sakuragi
Journal:  Front Microbiol       Date:  2011-12-09       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.